Knowledge of the powerful functional T-cell drivers can give complex engineered immune cell therapies the edge they need
Polyfunctional Strength Index (PSI™) detects the highly polyfunctional cell subsets, typically missed in bulk, that correlate to in vivo outcome in cell therapy. Isolating these differences helps you understand how to engineer the potency and durability needed throughout development & bioprocessing.
As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that IsoPlexis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T cell therapy before treatment.
“Only by pairing product data with clinical outcomes will commercial application of CAR T cells be further optimized and support enhanced safety and efficacy for patients.”